3. Characteristics of trials evaluating multiple micronutrients versus placebo.
| Trial ID | Country | Participants | Baseline HAART use (%) | Mean baseline CD4+ cell count (cells/mm3) |
Mean baseline viral load (copies/ml or log10 copies/mL) |
MMN dose1 | Duration of supplementation |
| Baum 2013 BWA | Botswana | HIV‐positive | 0 | 423 (median) | 11,800 (median) | High | 24 months |
| Guwatudde 2015 UG | Uganda | HIV‐positive | 49.82 | 145 (median) 137 (median) |
N/A | Standard | 18 months |
| Jiamton 2003 THA | Thailand | HIV‐positive | 0 | 244 (median) | 3.9 (1.0) | High | 48 weeks |
| Kelly 1999 ZMB | Zambia | HIV‐positive plus chronic diarrhoea | 0 | 291 (median) | N/A | High | 2 weeks |
| Kelly 2008 ZMB | Zambia | HIV‐positive | 03 | N/A | N/A | Standard | 1.9 years4 |
| McClelland 2004 KEN | Kenya | HIV‐positive | 0 | 294 (209) | 5.3 (0.9) | High | 6 weeks |
| Zhao 2010 CHN | China | HIV‐positive | Not stated | 417 (69) | Not stated | Standard | 6 months |
| Range 2006 TZA | Tanzania | HIV‐positive plus active TB | 0 | 363 (275) | 4.02 (0.98) | High | 8 months |
| Semba 2007 MWI | Malawi | HIV‐positive plus active TB | 0 | Not stated | 5.4 (median) | Standard | 24 months5 |
| Villamor 2008 TZA | Tanzania | HIV‐positive plus active TB | 0 | 305 (227) | 4.6 (1.0) | High | 24 months |
Abbreviations: HAART: highly active antiretroviral therapy; MMN: multiple micronutrient; TB: Tuberculosis
1Standard dose supplements provided most of the micronutrients at the level of the Dietary Recommended Intake (DRI). High‐dose supplements provided most of the micronutrients in multiples of the DRI. 2Guwatudde 2015 UG: participants who received ART for no longer than 6 months. The rest of the trial participants were initiated on ART at baseline. 3Kelly 2008 ZMB: we excluded participants taking HAART from the analysis of CD4 and viral load. 4Kelly 2008 ZMB was a cross‐over trial, with cross‐over at the end of 1.9 years. We did not include the outcome data for the period after cross‐over. 5Semba 2007 MWI: the median duration of follow‐up was 12.5 months, due to the introduction of ART programme.